Lungpacer
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
260 Sierra Drive 116, Exton, Pennsylvani...Phone Number
(484) 350-4530Website
www.lungpacer.comRevenue
$23.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Lungpacer
Lungpacer is a medical technology company focused on developing minimally invasive neurostimulation therapies that help critically ill patients regain independent breathing and reduce dependence on mechanical ventilation. The company specializes in diaphragm pacing and respiratory support technologies designed to strengthen the diaphragm, improve ventilator weaning outcomes, and support recovery in intensive care settings. Through its AeroPace system and ongoing clinical innovation, Lungpacer aims to transform respiratory and critical care by combining advanced neurostimulation technology with patient-centered therapeutic solutions for hospitals and healthcare providers worldwide.Explore more
Lungpacer Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lungpacer your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Lungpacer has new funding data
Product Launch: Get notified when Lungpacer launches new products
Check if Lungpacer has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Lungpacer recently announced quarterly report
Check out if Lungpacer is spiking on competitors!
Click to see if Lungpacer had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Lungpacer
Lungpacer, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Lungpacer as Masked Content
Find more new buyers
Compare Similar Companies to Lungpacer
Compare insights from companies similar to Lungpacer, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lungpacer is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lungpacer is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lungpacer.
Lungpacer financials insights
Gather financial insights about Lungpacer, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$19.6M
2021
Unspecified
$16M
2023
Series B
$20M
2026
Debt
$12M
Lungpacer Tech Stack
A closer look at the technologies used by Lungpacer
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Lungpacer News & Media
Lungpacer Achieves Commercial Milestone as Leading U.S. Hospital Performs First AeroPace® Procedures to Help Patients Liberate from Mechanical Ventilation
AeroPace temporary transvenous diaphragm neurostimulation system now available to help critically ill patients breathe independently faster AeroPace temporary transvenous diaphragm neurostimulation system now available to help critically ill patients breathe independently fasterLungpacer Medical Announces First Enrollments in STARI Trial of Next-Generation Neurostimulation Therapy
Lungpacer Medical today announced the first six patients enrolled in the groundbreaking STARI clinical trial.Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule
The Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-on Payment (NTAP) status for Lungpacer's AeroPace® System.American Journal of Respiratory and Critical Care Medicine Publishes Landmark Data on AeroPace® System's Breakthrough Results in Ventilator Weaning
International multi-center trial demonstrates AeroPace strengthens the diaphragm by 50%, weans more patients from ventilation, and reduces ventilator time by 3 days in patients difficult to wean from mechanical ventilation International multi-center trial demonstrates AeroPace strengthens the diaphragm by 50%, weans more patients from ventilation, and reduces ventilator time by 3 days in patients difficult to wean from mechanical ventilation
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lungpacer
Sign Up For FreeTo access detailed company insights
Lungpacer is a medical technology company focused on developing minimally invasive neurostimulation therapies that help critically ill patients regain independent breathing and reduce dependence on mechanical ventilation. The company specializes in diaphragm pacing and respiratory support technologies designed to strengthen the diaphragm, improve v... Read More
